Testing a new drug called ADCE-B05 in people with advanced solid cancers to find the safest and most effective dose and to understand its side effectsA First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors

Exclusion

• Treatment with systemic anticancer therapy, including any investigational agent within 3 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration
• Prior treatment with an ADC containing a topoisomerase I inhibitor payload
• Primary brain malignancy or known, untreated central nervous system (CNS) or leptomeningeal metastases, or symptoms suggesting CNS involvement for which treatment is required
• Other malignancy
• Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration
• Ongoing systemic infection requiring treatment with antibiotics, antivirals, or antimycotics, other than prophylactic treatment
• Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1
• Clinically significant cardiovascular disease
• Acute infection with human immunodeficiency virus (HIV)-1 or HIV-2
• Current active liver disease due to hepatitis B or hepatitis C
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis or pulmonary lymphangitic carcinomatosis